Therapeutic potential of pro-resolving mediators in diabetic kidney disease☆
Under a Creative Commons license
open access
Graphical abstract
Keywords
Tubulointerstitial fibrosis
Glomerulosclerosis
Hyperglycemia
Inflammation
Specialized pro-resolving mediators
Polyunsaturated fatty acids
Lipoxins
Abbreviations
ATLs
Aspirin-triggered lipoxins
CTGF/CCN2
Connective tissue growth factor
DKD
Diabetic Kidney Disease
DHA
Docosahexaenoic acid
EPA
Eicosapentaenoic acid
eNOS
Endothelial nitric oxide synthase
ESRD
End-stage renal disease
EGF
Epidermal growth factor
ECM
Extracellular Matrix
GBM
Glomerular basement membrane
GECs
Glomerular endothelial cells
ICAM1
Intracellular adhesion molecule-1
LX
Lipoxin
LO
Lipoxygenase
MaRs
Maresins
MCP1
Monocyte chemoattractant protein-1
NP
Nanoparticles
NO
Nitric oxide
PDGF
Platelet-derived growth factor
PUFA
Polyunsaturated Fatty Acid
PMN
Polymorphonuclear leukocyte
PDs
Protectins
Rvs
Resolvin
SPM
Specialized pro-resolving mediator
TGF-β1
Transforming growth factor beta-1
TIF
Tubulointerstitial fibrosis
UAE
Urinary albumin excretion
VEGF
Vascular endothelial growth factor
VCAM1
Vascular cell adhesion molecule-1
Cited by (0)
- ☆
This review is part of the Advanced Drug Delivery Reviews theme issue on "Fibrosis & Drug Delivery".
© 2021 The Author(s). Published by Elsevier B.V.